Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Blood (2025) 146 (Supplement 1): 5494.

https://doi.org/10.1182/blood-2025-5494

Published: 2025

Journal Articles

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Evgenii Shumilov, Maud Ngoya, Philipp Berning, Irma Khvedelidze, Sridhar Chaganti, Regis Peffault De Latour, Kate Cwynarski, Laura Magnano, Frank Kroschinsky, Johannes Clausen, José Antonio Pérez-Simón, Lawrence Ng, Luca Castagna, Georg Lenz, Anna Sureda, Gandhi Damaj, Ali Bazarbachi, Norbert Schmitz

Blood (2025) 146 (Supplement 1): 891.

https://doi.org/10.1182/blood-2025-891

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Blood (2025) 146 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2025-1937

Published: 2025

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas

Philipp Berning, Kazuya Fukasawa, Jahan Rahman, Ya-Hui Lin, Gilles Salles, Hans-Guido Wendel, Lorenzo Falchi, Santosha Vardhana

Blood (2025) 146 (Supplement 1): 556.

https://doi.org/10.1182/blood-2025-556

Published: 2025

Journal Articles

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

Blood (2025) 145 (17): 1943–1956.

https://doi.org/10.1182/blood.2024026886

Published: 2025

Includes: Supplemental data

Journal Articles

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Andrew F. Berdel, Julian Ronnacker, Daniela V. Wenge, Lina Kolloch, Philipp Berning, Linus Angenendt, Tobias Brix, Annette Westermann, Klaus Wethmar, Torsten Kessler, Andrea Kerkhoff, Rolf M. Mesters, Christian Reicherts, Jan-Henrik Mikesch, Wolfgang E. Berdel, Georg Lenz, Christoph Schliemann, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2024-193666

Published: 2024

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Zhangliang Cheng, Salim Oulghazi, Philipp Berning, David Fonseca-Arce, Kohei Kume, Jake Fontaine, Lai N Chan, Jaewoong Lee, Fang Yu, Zhijian Qian, Joo Y. Song, Wing Chung Chan, Jianjun Chen, Mark M Taketo, Hilde Schjerven, Markus Müschen

Blood (2024) 144 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2024-208125

Published: 2024

Journal Articles

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Blood (2024) 144 (Supplement 1): 4759.

https://doi.org/10.1182/blood-2024-202467

Published: 2024

Journal Articles

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2024-198763

Published: 2024

Journal Articles

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Philipp Berning, David Fonseca-Arce, Etienne Leveille, Shalin Kothari, Matthew S. Davids, Julia Jellusova, Markus Müschen

Blood (2024) 144 (Supplement 1): 1412.

https://doi.org/10.1182/blood-2024-208598

Published: 2024

Journal Articles

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 464.

https://doi.org/10.1182/blood-2024-202279

Published: 2024

Journal Articles

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Lina Kolloch, Philipp Berning, Simon Call, Matthias Floeth, Julia Marx, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2024) 144 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2024-203502

Published: 2024

Journal Articles

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 3818.

https://doi.org/10.1182/blood-2024-211227

Published: 2024

Journal Articles

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2023-180723

Published: 2023

Journal Articles

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Lina Kolloch, Philipp Berning, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2023) 142 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2023-180078

Published: 2023

Journal Articles

Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells

Blood (2023) 142 (Supplement 1): 441.

https://doi.org/10.1182/blood-2023-184788

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 2306–2307.

https://doi.org/10.1182/blood-2022-164637

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) - Treatment Options and Outcomes at a Large AML Referral Center

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only